Camrelizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | PD1 |
| Clinical data | |
| Other names | SHR-1210 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Camrelizumab (SHR-1210) (INN) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma. PD-1 is programmed cell death protein 1.
The drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019, camrelizumab is undergoing Phase II/III trials.